Base de dados : MEDLINE
Pesquisa : C04.834.818 [Categoria DeCS]
Referências encontradas : 3656 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 366 ir para página                         

  1 / 3656 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29179269
[Au] Autor:Huang AJ; Zhao Y; Zou XL; Yan J; Zhao C; Cui SH; Li YY; Ren LH; Li JR; Li MZ; Wang Y; Wang JL; Wei LH
[Ad] Endereço:Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
[Ti] Título:[Study on clinical management of HPV(+)/Pap(-) during cervical cancer screening].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;52(11):745-750, 2017 Nov 25.
[Is] ISSN:0529-567X
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To study the clinical management way for HPV(+)/papanicolaou (Pap)(-) during cervical cancer screening. To analyze retrospectively the data from the patients who had loop electrical excision procedure (LEEP) for biopsy confirmed cervical intraepithelial neoplasia (CIN) â…¡ in Peking University People's Hospital from Jan. 2010 to Dec. 2014. (1) For biopsy confirmed CIN â…¡, HPV positive rate was 98.5% (135/137), Pap test positive [≥atypical squamous cell of undetermined significance (ASCUS)] rate was 69.3% (95/137), there was significant difference between them (χ(2)=43.32, 0.01). (2) For the 42 patients with HPV(+)/Pap(-), whose cytology slides were reviewed again. Among them, the interpretations of there were 16 cases confirmed as the same before, while 26 cases were changed to abnormal (≥ASCUS). Cytology be misdiagnosed was 19.0% (26/137) at the first review. Among the 26 cases, 13 (50.0%) cases were missed for the little amount of abnormal cells, 8 (30.8%) cases for mild atypical morphology changed; the other 5 (19.2%) cases missed for stain problems. (3) For the cervical LEEP samples, 37 cases of the pathology diagnosis were upgrade to CIN â…¢(+), among them, 2 cases of microinvasive cervical carcinoma, 1 case of invasive cancer, 34 cases of CIN â…¢; 37 cases were CINâ…  or no lesion found; 63 cases were still CIN â…¡. Four to six months later after LEEP, the cytology abnormal rate was 11.7% (16/137), and the HR-HPV positive rate was 34.3% (47/137). Compared with cytology alone, cytology combined with HPV testing increase the sensitivity of cervical high grade lesion. For the cases of HPV(+)/Pap(-) cases, the cytology slides should be reviewed. The quality control of cervical exfoliate sample collection and interpretation should be strengthened. LEEP procedure is not only a treatment method, but also it could provide samples to confirm the diagnosis.
[Mh] Termos MeSH primário: Neoplasia Intraepitelial Cervical/patologia
Teste de Papanicolaou
Papillomaviridae/isolamento & purificação
Neoplasias do Colo do Útero/patologia
Esfregaço Vaginal
[Mh] Termos MeSH secundário: Adulto
Neoplasia Intraepitelial Cervical/virologia
Detecção Precoce de Câncer
Feminino
Seres Humanos
Meia-Idade
Infecções por Papillomavirus/diagnóstico
Estudos Retrospectivos
Sensibilidade e Especificidade
Manejo de Espécimes
Displasia do Colo do Útero
Neoplasias do Colo do Útero/virologia
Esfregaço Vaginal/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2017.11.006


  2 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215531
[Au] Autor:Silverberg MJ; Leyden WA; Chi A; Gregorich S; Huchko MJ; Kulasingam S; Kuppermann M; Seto A; Smith-McCune KK; Sawaya GF
[Ad] Endereço:Division of Research, Kaiser Permanente, Oakland, California; the Department of Epidemiology and Biostatistics, the School of Pharmacy, the Department of Medicine, and the Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California; the Department of Obstetrics and Gynecology and the Global Health Institute, Duke University, Durham, North Carolina; and the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
[Ti] Título:Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia.
[So] Source:Obstet Gynecol;131(1):47-55, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To estimate the risk of cervical intraepithelial neoplasia grade 2, 2-3, 3, adenocarcinoma in situ, or cancer (CIN 2 or worse) among women with human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression. METHODS: We performed a case-control study of 20,146 women with incident CIN 2 or worse and 5:1 age-matched, incidence-density selected women in a control group (n=100,144) enrolled in an integrated health care system from 1996 to 2014. Adjusted rate ratios (RRs) from conditional logistic regression were obtained for HIV status (stratified by CD4 T-cells), solid organ transplant history, and immunosuppressive medication use. RESULTS: Risk of CIN 2 or worse was increased among women with HIV (n=36 women in the case group and 79 women in the control group; adjusted RR 2.0, 95% CI 1.3-3.0) compared with those without HIV and in solid organ transplant recipients (n=51 women in the case group and 68 women in the control group; RR 3.3, 95% CI 2.3-4.8) compared with women without a prior transplant. The highest risks were among women with HIV and less than 200 CD4 T-cells/microliter (n=9 women in the case group and eight women in the control group; RR 5.6, 95% CI 2.1-14.7) compared with those without HIV and in solid organ transplant recipients prescribed three or greater immunosuppressive medication classes (n=32 women in the case group and 33 women in the control group; RR 4.1, 95% CI 2.5-6.8) compared with women without a prior transplant and zero medication classes. No increased risks were observed for women with HIV and 500 or greater CD4 T-cells/microliter (n=9 women in the case group and 43 women in the control group; RR 0.8, 95% CI 0.4-1.7) compared with those without HIV or women without prior solid organ transplantation prescribed two or fewer immunosuppressive medication classes (n=1,262 women in the case group and 6,100 women in the control group; RR 0.95, 95% CI 0.89-1.01) compared with women without and a prior transplant and zero medication classes. CONCLUSION: Risk of CIN 2 or worse is increased in women with a prior solid organ transplant or who have HIV and CD4 cells/microliter less than 500 but not in women with HIV and higher CD4 levels or in women without a prior solid organ transplant but who are prescribed only one or two immunosuppressive medication classes.
[Mh] Termos MeSH primário: Adenocarcinoma/virologia
Infecções por HIV/imunologia
Displasia do Colo do Útero/imunologia
Displasia do Colo do Útero/virologia
Neoplasias do Colo do Útero/imunologia
Neoplasias do Colo do Útero/virologia
[Mh] Termos MeSH secundário: Adenocarcinoma/epidemiologia
Adenocarcinoma/imunologia
Adenocarcinoma/patologia
Adulto
Distribuição por Idade
California
Estudos de Casos e Controles
Feminino
Infecções por HIV/complicações
Seres Humanos
Imunossupressão
Incidência
Modelos Logísticos
Meia-Idade
Invasividade Neoplásica/patologia
Estadiamento de Neoplasias
Prognóstico
Valores de Referência
Sistema de Registros
Medição de Risco
Displasia do Colo do Útero/epidemiologia
Displasia do Colo do Útero/patologia
Neoplasias do Colo do Útero/epidemiologia
Neoplasias do Colo do Útero/patologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002371


  3 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28870901
[Au] Autor:Vora M; Alattia LA; Ansari J; Ong M; Cotelingam J; Coppola D; Shackelford R
[Ad] Endereço:Department of Pathology and Translational Pathobiology, LSU Health, Shreveport, LA, U.S.A.
[Ti] Título:Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
[So] Source:Anticancer Res;37(9):4821-4825, 2017 09.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Nicotinamide phosphoribosyl transferase (Nampt) catalyses the rate-limiting step of the mammalian nicotinamide adenine dinucleotide (NAD) salvage pathway. Nampt is highly expressed in several epithelial and mesenchymal neoplasms, where is promotes cell-cycle progression ans chemotherapy resistance. To our knowledge, alterations in Nampt expression have not been examined in cervical intraepithelial neoplasia (CIN) or squamous cell carcinoma (SCC). MATERIALS AND METHODS: We performed immunohistochemical analysis for Nampt using tissue microarrays on 14 samples of benign cervical squamous epithelium and 15 CIN I, 15 CIN II, and 13 samples of CIN III. The SCCs included 5 low-grade, 67 intermediate-grade, and 81 high-grade tumors. RESULTS: Nampt levels increased with increased CIN grades were compared to benign cervical squamous epithelium. Similarly, Nampt levels increased with increasing SCC grade. CONCLUSION: Nampt expression is a reliable marker of progression in cervical dysplasia and SCC.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Citocinas/metabolismo
Progressão da Doença
Nicotinamida Fosforribosiltransferase/metabolismo
Displasia do Colo do Útero/enzimologia
Displasia do Colo do Útero/patologia
[Mh] Termos MeSH secundário: Colo do Útero/patologia
Feminino
Seres Humanos
Imuno-Histoquímica
Análise Serial de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Cytokines); EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase); EC 2.4.2.12 (nicotinamide phosphoribosyltransferase, human)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  4 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28796684
[Au] Autor:Lipkind HS; Vazquez-Benitez G; Nordin JD; Romitti PA; Naleway AL; Klein NP; Hechter RC; Jackson ML; Hambidge SJ; Lee GM; Sukumaran L; Kharbanda EO
[Ad] Endereço:Department of Obstetrics, Gynecology, & Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut; HealthPartners Institute, Minneapolis, Minnesota; the Department of Epidemiology, University of Iowa, Iowa City, Iowa; the Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon; the Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California; the Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; Group Health Research Institute, Seattle, Washington; the Institute for Health Research, Kaiser Permanente Colorado and Ambulatory Care Services, Denver Health, Denver, Colorado; Harvard Pilgrim Health Care Institute & Harvard Medical School, Boston, Massachusetts; and the Centers for Disease Control and Prevention, Atlanta, Georgia.
[Ti] Título:Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.
[So] Source:Obstet Gynecol;130(3):599-608, 2017 Sep.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate whether quadrivalent human papillomavirus vaccine (4vHPV) administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects. METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. Insured women 13-27 years old with singleton pregnancies and a live birth from January 1, 2007, through September 1, 2013, who received 4vHPV during the periconceptional period (2 weeks before to 2 weeks after their last menstrual period), during pregnancy, or during both periods combined were compared with women who had a live birth during the same time period and received 4vHPV 4-18 months before their last menstrual period. We examined risks of gestational diabetes, hypertensive disorders of pregnancy, chorioamnionitis, preterm birth, small-for-gestational-age birth, and selected major structural birth defects in offspring. We estimated relative risks associated with receipt of 4vHPV during the periconceptional period, during pregnancy, and both exposure periods combined using a generalized linear model with Poisson distribution including a propensity score that included relevant maternal demographic and pregnancy characteristics. RESULTS: Of 92,579 potentially eligible pregnant women, 720 received 4vHPV during the periconceptional period, 638 received 4vHPV during pregnancy, and 8,196 received 4vHPV during the comparison period. Administration of 4vHPV during pregnancy was not associated with increased risk of adverse obstetric events, birth outcomes. Preterm birth occurred in 7.9% of pregnancies with vaccine exposures during pregnancy compared with 7.6% of pregnancies with vaccination in the comparison period (adjusted relative risk 0.97, 95% CI 0.72-1.3). Major structural birth defects were diagnosed in 2.0% of pregnancies with vaccine exposure during pregnancy compared with 1.8% of pregnancies with vaccine exposure during the comparison period (adjusted prevalence ratio 1.0, 95% CI 0.52-1.9). Results were similar for 4vHPV exposure during the periconceptional period. CONCLUSION: Quadrivalent HPV vaccine inadvertently administered in pregnancy or during the periconceptional period was not associated with adverse pregnancy or birth outcomes.
[Mh] Termos MeSH primário: Vacina Quadrivalente Recombinante contra HPV tipos 6, 11, 16, 18/efeitos adversos
Infecções por Papillomavirus/prevenção & controle
Cuidado Pré-Concepcional
Complicações Infecciosas na Gravidez/prevenção & controle
Cuidado Pré-Natal
Displasia do Colo do Útero/prevenção & controle
[Mh] Termos MeSH secundário: Aborto Espontâneo/epidemiologia
Adolescente
Adulto
Sistemas de Notificação de Reações Adversas a Medicamentos
Estudos de Coortes
Anormalidades Congênitas/epidemiologia
Feminino
Seres Humanos
Recém-Nascido
Gravidez
Resultado da Gravidez
Nascimento Prematuro/epidemiologia
Estudos Retrospectivos
Natimorto/epidemiologia
Estados Unidos/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002191


  5 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28767912
[Au] Autor:Fregnani CMS; Fregnani JHTG; Paiva CE; Barroso EM; Camargos MG; Tsunoda AT; Longatto-Filho A; Paiva BSR
[Ad] Endereço:Hospital de Câncer de Barretos, Barretos, SP, Brazil.
[Ti] Título:Translation and cultural adaptation of the Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia (FACIT-CD) to evaluate quality of life in women with cervical intraepithelial neoplasia.
[So] Source:Einstein (Sao Paulo);15(2):155-161, 2017 Apr-Jun.
[Is] ISSN:2317-6385
[Cp] País de publicação:Brazil
[La] Idioma:eng; por
[Ab] Resumo:Objective: To translate and perform the cultural adaptation of the tool Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia (FACIT-CD) to the Portuguese language. Methods: A descriptive cross-sectional study, with translation and cultural adaptation of the assessment tool performed according to international guidelines and the Functional Assessment of Chronic Illness Therapy (FACIT) protocol group. It involved eight experts, six from Brazil, one from Portugal and one from the United States. After translation and back-translation of the tool, the semantic analysis process was carried out. We randomly included 20 women aged between 18 and 70 years with altered cervical cytology exam, seen at the Department of Prevention and Gynecologic Oncology - Hospital de Câncer de Barretos. Results: The sample consisted of women with low education level. In the first pre-test, ten women participated and half of them considered the questions CD1, CD2 and CD3 as difficult, because they did not understand the meaning of the term "pelvic area". The question CD5, "I worry about spreading the infection", was also considered difficult to understand by five women. After the reconsideration of the expert committee and FACIT group, the second pre-test was performed. At this stage, we concluded that the previously raised understanding problems had been solved. Conclusion: The translated version of FACIT-CD in universal Portuguese language is equivalent to the original version in English and was easily understood by patients with cervical intraepithelial neoplasia. Objetivo: Traduzir e adaptar o instrumento Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia (FACIT-CD), para a língua portuguesa. Métodos: Estudo descritivo, transversal, com metodologia de tradução e adaptação cultural de instrumento de avaliação, realizado por meio de diretrizes internacionais e seguindo o protocolo do grupo Functional Assessment of Chronic Illness Therapy (FACIT). Envolveu oito especialistas, sendo seis nativos do Brasil, um de Portugal e um dos Estados Unidos. Ao término do processo de tradução e retrotradução, deu-se início ao processo de análise semântica. Foram incluídas aleatoriamente 20 mulheres entre 18 e 70 anos com exame de citologia cervical alterado, atendidas no Departamento de Prevenção e Ginecologia Oncológica do Hospital de Câncer de Barretos. Resultados: A amostra foi composta por mulheres com baixa escolaridade. No primeiro pré-teste participaram dez mulheres, sendo que a metade considerou as questões CD1, CD2 e CD3 difíceis por não compreenderem o significado do termo "região pélvica". A questão CD5, "Estou preocupada em disseminar a infecção", também foi considerada de difícil entendimento por cinco mulheres. Após as reconsiderações do comitê de especialistas e do grupo FACIT, foi realizado o segundo pré-teste. Nesta fase, pode-se concluir que os problemas de entendimento anteriores foram resolvidos. Conclusão: A versão traduzida do FACIT-CD é equivalente à versão original em inglês e em língua portuguesa universal, sendo facilmente compreendida pelas pacientes com neoplasia intraepitelial cervical.
[Mh] Termos MeSH primário: Qualidade de Vida/psicologia
Inquéritos e Questionários
Traduções
Displasia do Colo do Útero/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Brasil
Comparação Transcultural
Estudos Transversais
Escolaridade
Feminino
Seres Humanos
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE


  6 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723743
[Au] Autor:Li K; Yin R; Li Q; Wang D
[Ad] Endereço:aThe Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu bKey Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China.
[Ti] Título:Analysis of HPV distribution in patients with cervical precancerous lesions in Western China.
[So] Source:Medicine (Baltimore);96(29):e7304, 2017 Jul.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cervical human papillomavirus (HPV) infection is a dangerous disease, whose subtypes exhibit different distribution patterns in particular countries, regions, and races. In this study, the HPV distribution in patients with cervical precancerous lesions in Western China was investigated to assess a probability for prevention of cervical cancer and the clinical application of an HPV vaccine in China. The retrospective study of patients with different HPV subtypes and cervical precancerous lesions, who have undergone loop eelectrosurgical excision procedure, cold knife conization, or a total hysterectomy in our hospital from January 2016 to August 2016, was performed. All patients were tested for 27 HPV subtypes via the liquid suspension chip technology (Luminex 200). A total of 3393 cases of cervical intraepithelial neoplasia (CIN) were investigated, including 1098 cases of CIN I, 762 cases of CIN II, and 1533 cases of CIN III. The overall HPV infection rate was 82.58%. The high-risk HPV infection rate was 76.61%, and the low-risk rate was 9.88%. The most common 5 subtypes were HPV16, HPV52, HPV58, HPV33, and HPV18. The patients were grouped into 6 age groups: ≤20, 21 to 30, 31 to 40, 41 to 50, 50 to 64, and ≥65. The HPV subtypes' distribution varied across different age groups. In patients with cervical precancerous lesions in Western China, the top 5 HPV subtypes with the highest infection rates were HPV16, HPV52, HPV58, HPV33, and HPV18. The rate of cervical precancerous lesions unrelated to HPV was 17.42%. Thus, HPV screening with no cytology may leave unobserved about 20% of cervical precancerous lesions, which is worth of significant clinical attention.
[Mh] Termos MeSH primário: Papillomaviridae
Infecções por Papillomavirus/epidemiologia
Displasia do Colo do Útero/epidemiologia
Displasia do Colo do Útero/virologia
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
China
Feminino
Seres Humanos
Meia-Idade
Infecções por Papillomavirus/cirurgia
Estudos Retrospectivos
Displasia do Colo do Útero/cirurgia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007304


  7 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28651012
[Au] Autor:Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydryp ML; Håkansson U; Sparén P; Borgfeldt C
[Ad] Endereço:Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:The economic burden of human papillomavirus-related precancers and cancers in Sweden.
[So] Source:PLoS One;12(6):e0179520, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: High-risk (HR) human papillomavirus (HPV) infection is an established cause of malignant disease. We used a societal perspective to estimate the cost of HR HPV-related cervical, vulvar, vaginal, anal, and penile precancer and cancer, and oropharyngeal cancer in Sweden in 2006, 1 year before HPV vaccination became available in the country. MATERIALS AND METHODS: This prevalence-based cost-of-illness study used diagnosis-specific data from national registries to determine the number of HR HPV-related precancers and cancers. The HR HPV-attributable fractions of these diseases were derived from a literature review and applied to the total burden to estimate HR HPV-attributable costs. Direct costs were based on health care utilization and indirect costs on loss of productivity due to morbidity (i.e., sick leave and early retirement) and premature mortality. RESULTS: The total annual cost of all HR HPV-attributable precancers and cancers was €94 million (€10.3/inhabitant). Direct costs accounted for €31.3 million (€3.4/inhabitant) of the total annual cost, and inpatient care amounted to €20.7 million of direct costs. Indirect costs made up €62.6 million (€6.9/inhabitant) of the total annual cost, and premature mortality amounted to €36 million of indirect costs. Cervical precancer and cancer was most costly (total annual cost €58.4 million). Among cancers affecting both genders, anal precancer and cancer, and oropharyngeal cancer were the most costly (€11.2 million and €11.9 million, respectively). For oropharyngeal cancer, males had the highest health care utilization and represented 71% of the total annual cost. Penile precancer and cancer was least costly (€2.6 million). CONCLUSION: The economic burden of HR HPV-related precancers and cancers is substantial. The disease-related management and treatment costs we report are relevant as a point of reference for future economic evaluations investigating the overall benefits of HPV vaccination in females and males in Sweden.
[Mh] Termos MeSH primário: Neoplasias do Ânus/economia
Efeitos Psicossociais da Doença
Neoplasias dos Genitais Femininos/economia
Infecções por Papillomavirus/economia
Vacinas contra Papillomavirus/economia
Neoplasias Penianas/economia
Displasia do Colo do Útero/economia
[Mh] Termos MeSH secundário: Adulto
Neoplasias do Ânus/virologia
Feminino
Neoplasias dos Genitais Femininos/virologia
Custos de Cuidados de Saúde
Seres Humanos
Masculino
Papillomaviridae
Infecções por Papillomavirus/complicações
Infecções por Papillomavirus/virologia
Neoplasias Penianas/virologia
Suécia
Displasia do Colo do Útero/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179520


  8 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28591310
[Au] Autor:de Oliveira GR; Vieira VC; Ávila EC; Finger-Jardim F; Caldeira TD; Gatti FA; Gonçalves CV; Oliveira SG; da Hora VP; Soares MA; de Martinez AM
[Ad] Endereço:Universidade Federal do Rio Grande, Escola de Medicina, Laboratório de Biologia Molecular, Rio Grande, RS, Brasil.
[Ti] Título:Human papillomavirus type distribution and HPV16 intratype diversity in southern Brazil in women with and without cervical lesions.
[So] Source:Mem Inst Oswaldo Cruz;112(7):492-498, 2017 Jul.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Increasing evidence suggests that human papillomavirus (HPV) intratype variants (specific lineages and sublineages) are associated with pathogenesis and progression from HPV infection to persistence and the development of cervical cancer. OBJECTIVES: This study aimed to verify the prevalence of HPV infection and distribution of HPV types and HPV16 variants in southern Brazil in women with normal cytology or intraepithelial lesions. METHODS: HPV typing was determined by L1 gene sequencing. To identify HPV16 variants, the LCR and E6 regions were sequenced, and characteristic single nucleotide variants were identified. FINDINGS: A total of 445 samples were studied, with 355 from cervical scrapes and 90 from cervical biopsies. HPV was detected in 24% and 91% of these samples, respectively. The most prevalent HPV types observed were 16 (cervical, 24%; biopsies, 57%) and 58 (cervical, 12%; biopsies, 12%). Seventy-five percent of the HPV16-positive samples were classified into lineages, with 88% defined as lineage A, 10% as lineage D, and 2% as lineage B. MAIN CONCLUSIONS: This study identified a high frequency of European and North American HPV16 lineages, consistent with the genetic background of the human population in southern Brazil.
[Mh] Termos MeSH primário: Variação Genética/genética
Papillomavirus Humano 16/genética
Infecções por Papillomavirus/virologia
Displasia do Colo do Útero/virologia
Neoplasias do Colo do Útero/virologia
[Mh] Termos MeSH secundário: Adulto
Brasil
Estudos Transversais
DNA Viral/genética
Feminino
Seres Humanos
Reação em Cadeia da Polimerase
Fatores Socioeconômicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Viral)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE


  9 / 3656 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28390560
[Au] Autor:Heinlen L; Chakravarty EF
[Ad] Endereço:Division of Rheumatology, Oklahoma University Health Sciences Center, 1100 N. Lindsay Avenue, Oklahoma City, OK 73104, USA.
[Ti] Título:Reproductive Health Screening in Women with Autoimmune Diseases.
[So] Source:Rheum Dis Clin North Am;43(2):161-171, 2017 May.
[Is] ISSN:1558-3163
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although the female predominance of autoimmune diseases is not completely understood, sex hormones are thought to play a role. Attention to lifelong reproductive health is especially important for women with autoimmune disorders. Many of these women require long-term immunosuppressive therapy that may affect their ability to clear infections, including viruses, and may alter natural tumor surveillance mechanisms. As a result, women with autoimmune diseases may have different risks for common reproductive-related malignancies that may in turn affect screening guidelines and other preventive measures, including vaccination. Women with autoimmune diseases need to adhere diligently to screening recommendations.
[Mh] Termos MeSH primário: Doenças Autoimunes/epidemiologia
Neoplasias da Mama/diagnóstico
Infecções por Papillomavirus/diagnóstico
Displasia do Colo do Útero/diagnóstico
Neoplasias do Colo do Útero/diagnóstico
[Mh] Termos MeSH secundário: Artrite Reumatoide/epidemiologia
Doenças Autoimunes/tratamento farmacológico
Neoplasias da Mama/induzido quimicamente
Neoplasias da Mama/epidemiologia
Detecção Precoce de Câncer/métodos
Feminino
Fidelidade a Diretrizes
Seres Humanos
Imunossupressores/efeitos adversos
Lúpus Eritematoso Sistêmico/epidemiologia
Infecções por Papillomavirus/epidemiologia
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/uso terapêutico
Cooperação do Paciente
Guias de Prática Clínica como Assunto
Displasia do Colo do Útero/epidemiologia
Neoplasias do Colo do Útero/induzido quimicamente
Neoplasias do Colo do Útero/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE


  10 / 3656 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388819
[Au] Autor:Bogani G; Taverna F; Lombardo C; Borghi C; Martinelli F; Signorelli M; Leone Roberti Maggiore U; Chiappa V; Scaffa C; Ditto A; Lorusso D; Raspagliesi F
[Ad] Endereço:Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy.
[Ti] Título:Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology.
[So] Source:Int J Gynaecol Obstet;138(1):62-68, 2017 Jul.
[Is] ISSN:1879-3479
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the outcomes of women diagnosed with high-risk HPV without cytology evidence of cervical dysplasia. METHODS: The present retrospective observational study enrolled consecutive women aged at least 18 years diagnosed with high-risk HPV types with negative cytology results at the National Cancer Institute, Milan, Italy, between January 1, 2005, and December 31, 2015. The development of cervical intraepithelial neoplasia (CIN) was assessed. RESULTS: There were 212 patients with high-risk HPV infections with negative cytology included in the analysis. After a mean ± SD follow-up period of 48 ± 33 months, 65 (30.7%) and 26 (12.3%) patients had developed cytologic or histologic cervical dysplasia (low-grade squamous intraepithelial lesion [LSIL]/CIN1+) and high-grade cervical dysplasia (CIN2+), respectively. No patients had invasive cancer. No correlations were observed between type-specific HPV infections and LSIL/CIN1+ and CIN2+. HPV persistence correlated with both LSIL/CIN1+ (P<0.001) and CIN2+ (P<0.001) in univariate analyses; a 6-month increase in HPV persistence was associated with increased risk of developing LSIL/CIN1+ (P=0.010) and CIN2+ (P=0.012) in multivariate analyses. CONCLUSIONS: Regardless of cytology findings, patients diagnosed with high-risk HPV types should receive strict colposcopy follow-up, particularly with persistent HPV infections. Further prospective studies are needed to defined optimal surveillance strategies for these patients.
[Mh] Termos MeSH primário: Neoplasia Intraepitelial Cervical/patologia
Papillomaviridae/patogenicidade
Infecções por Papillomavirus/patologia
Displasia do Colo do Útero/patologia
[Mh] Termos MeSH secundário: Adulto
Neoplasia Intraepitelial Cervical/diagnóstico
Neoplasia Intraepitelial Cervical/virologia
Colposcopia
Citodiagnóstico
Feminino
Seres Humanos
Meia-Idade
Papillomaviridae/isolamento & purificação
Infecções por Papillomavirus/complicações
Infecções por Papillomavirus/virologia
Estudos Retrospectivos
Displasia do Colo do Útero/diagnóstico
Displasia do Colo do Útero/virologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1002/ijgo.12170



página 1 de 366 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde